Meeting
2013 Gastrointestinal Cancers Symposium
Japanese cohort study of first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC) containing fluorouracil, oxaliplatin, and bevacizumab: EMERaLD study, first report.
Authors
Keisei Taku
Shizuoka General Hospital
Keisei Taku , Kou Ohata , Toraji Amano , Yasuo Ohashi , Kentaro Yamazaki , Masaya Watanabe , Shinsuke Satou , Takeshi Ooshima , Go Nishikawa , Hidekazu Hirano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
UMIN000006392
Citation
J Clin Oncol 31, 2013 (suppl 4; abstr586)
DOI
10.1200/jco.2013.31.4_suppl.586
Abstract #
586
Poster Bd #
E34
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Observational cohort study of first-line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin(OX)+BV and oral FU/OX+BV.
First Author: Kazuteru Hatanaka
Poster
2012 Gastrointestinal Cancers Symposium
Phase II intermittent (or stop and go) l-OHP administration of first-line bevacizumab (BV) plus mFOLFOX6 or CapeOX therapies in Japanese patients with mCRC: The interim report of t-CORE0901.
First Author: Makio Gamoh
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Anlotinib combined with penpulimab and hepatic artery infusion chemotherapy (HAIC) in the first-line treatment of unresectable hepatocellular carcinoma.
First Author: Gong-Rang Chen
Poster
2023 ASCO Annual Meeting
Impact of sex on the efficacy of first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus Y90-radioembolization in patients with metastatic colorectal cancer: An exploratory, retrospective analysis of the phase III SIRFLOX trial.
First Author: Kathrin Heinrich